Measuring response in the gastrointestinal tract in systemic sclerosis

被引：60

作者：

Khanna, Dinesh ^{[1
]}

Nagaraja, Vivek ^{[1
]}

Gladue, Heather ^{[1
]}

Chey, William ^{[1
]}

Pimentel, Mark ^{[2
]}

Frech, Tracy ^{[3
]}

机构：

[1] Univ Michigan, Ann Arbor, MI 48109 USA

[2] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA

[3] Univ Utah, Salt Lake City, UT USA

来源：

CURRENT OPINION IN RHEUMATOLOGY | 2013年 / 25卷 / 06期

关键词：

gastrointestinal involvement; outcome measures; systemic sclerosis; UCLA SCTC GIT 2; 0; QUALITY-OF-LIFE; CARDINAL SYMPTOM INDEX; DYSPEPSIA QOLRAD QUESTIONNAIRE; REFLUX DISEASE QUESTIONNAIRE; FECAL INCONTINENCE; CLINICAL-TRIAL; GASTROESOPHAGEAL-REFLUX; NUTRITIONAL-STATUS; LOS-ANGELES; SCLERODERMA;

D O I：

10.1097/01.bor.0000434668.32150.e5

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Purpose of reviewGastrointestinal tract (GIT) involvement in systemic sclerosis (scleroderma, SSc) is the most common internal complication. This review discusses the outcome measures to capture GIT involvement in clinical care and trials.Recent findingsPatient-reported outcome measures have been validated (UCLA Scleroderma Clinical Trial Consortium GIT 2.0 and NIH PROMIS scales) in SSc-GIT. Multiple objective measures are available to assess mucosal involvement and motility in GIT. However, these need to be validated in SSc for trials.SummaryGIT is a common cause of morbidity and has negative impact on quality of life in SSc. Recommendations are given for trial design and evaluation of GIT involvement in SSc.

引用

页码：700 / 706

页数：7

共 65 条

[1] FLQAI - A Questionnaire on Quality of Life in Fecal Incontinence: German Translation and Validation of Rockwood et al.'s (2000) Fecal Incontinence Quality of Life Scale (FIQLS) [J].